JLE

Epileptic Disorders

MENU

Evaluation of real-world effectiveness of perampanel in Japanese adults and older adults with epilepsy Volume 24, issue 1, February 2022

  • [1] Sillanpää M., Gissler M., Schmidt D. Efforts in epilepsy prevention in the last 40 years: lessons from a large nationwide study. JAMA Neurol. 2016;73:390-395.
  • [2] Ramsay R.E., Macias F.M., Rowan A.J. Diagnosing epilepsy in the elderly. Int Rev Neurobiol. 2007;81:129-151.
  • [3] Lhatoo S.D., Johnson A.L., Goodridge D.M., MacDonald B.K., Sander J.W., Shorvon S.D. Mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort. Ann Neurol. 2001;49:336-344.
  • [4] Liu S., Yu W., Lü Y. The causes of new-onset epilepsy and seizures in the elderly. Neuropsychiatr Dis Treat. 2016;12:1425-1434.
  • [5] Hernández-Ronquillo L., Adams S., Ballendine S., Téllez-Zenteno J.F. Epilepsy in an elderly population: classification, etiology and drug resistance. Epilepsy Res. 2018;140:90-94.
  • [6] Werhahn K.J., Trinka E., Dobesberger J., Unterberger I., Baum P., Deckert-Schmitz M. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia. 2015;56:450-459.
  • [7] Zilles K., Qü M.S., Köhling R., Speckmann E.J. Ionotropic glutamate and GABA receptors in human epileptic neocortical tissue: quantitative in vitro receptor autoradiography. Neuroscience. 1999;94:1051-1061.
  • [8] Löscher W., Schmidt D. Epilepsy: perampanel-new promise for refractory epilepsy? Nat Rev Neurol. 2012;8:661-662.
  • [9] Rogawski M.A. AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol Scand Suppl. 2013;197:9-18.
  • [10] Hanada T., Hashizume Y., Tokuhara N., Takenaka O., Kohmura N., Ogasawara A. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52:1331-1340.
  • [11] Turski L., Jacobsen P., Honoré T., Stephens D.N. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. J Pharmacol Exp Ther. 1992;260:742-747.
  • [12] French J.A., Krauss G.L., Biton V., Squillacote D., Yang H., Laurenza A. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79:589-596.
  • [13] French J.A., Krauss G.L., Steinhoff B.J., Squillacote D., Yang H., Kumar D. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54:117-125.
  • [14] Krauss G.L., Serratosa J.M., Villanueva V., Endziniene M., Hong Z., French J. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78:1408-1415.
  • [15] Yamamoto T., Lim S.C., Ninomiya H., Kubota Y., Shin W.C., Kim D.W. Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: the open-label Study 342 (FREEDOM Study). Epilepsia Open. 2020;5:274-284.
  • [16] Steinhoff B.J., Patten A., Williams B., Malhotra M. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: a pooled post hoc analysis of four randomized, double-blind, phase III studies. Epilepsia. 2020;61:278-286.
  • [17] Leppik I.E., Wechsler R.T., Williams B., Yang H., Zhou S., Laurenza A. Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials. Epilepsy Res. 2015;110:216-220.
  • [18] Stefan H., May T.W., Pfäfflin M., Brandt C., Füratsch N., Schmitz B. Epilepsy in the elderly: comparing clinical characteristics with younger patients. Acta Neurol Scand. 2014;129:283-293.
  • [19] Tanaka A., Akamatsu N., Shouzaki T., Toyota T., Yamano M., Nakagawa M. Clinical characteristics and treatment responses in new-onset epilepsy in the elderly. Seizure. 2013;22:772-775.
  • [20] French J.A., Gil-Nagel A., Malerba S., Kramer L., Kumar D., Bagiella E. Time to prerandomization monthly seizure count in perampanel trials: a novel epilepsy endpoint. Neurology. 2015;84:2014-2020.
  • [21] Nishida T., Lee S.K., Inoue Y., Saeki K., Ishikawa K., Kaneko S. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study. Acta Neurol Scand. 2018;137:392-399.
  • [22] Glauser T., Laurenza A., Yang H., Williams B., Ma T., Fain R. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: a phase III post-hoc analysis. Epilepsy Res. 2016;119:34-40.
  • [23] Krauss G.L., Perucca E., Kwan P., Ben-Menachem E., Wang X.F., Shih J.J. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: study 307. Epilepsia. 2018;59:866-876.
  • [24] Villanueva V., Garcés M., López-González F.J., Rodriguez-Osorio X., Toledo M., Salas-Puig J. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: the FYDATA study. Epilepsy Res. 2016;126:201-210.